Stephen W. Ranere

Partner
Boston
  • 200 Clarendon Street
  • Boston, MA 02116
  • USA
Profile Experience

Stephen Ranere is a partner in the Boston office of Latham & Watkins and a member of the firm's Emerging Companies Practice. He represents emerging companies and venture capital firms involved in the technology and life sciences industries. His practice focuses on: general corporate counseling, early stage company formation and strategy, initial through late stage venture capital financings, mergers and acquisitions, and public securities offerings.

Mr. Ranere was a member of the Suffolk University Law Review and was awarded the Daniel J. Fern Award for highest grade point average.

Prior to law school, Mr. Ranere held business development positions with Sophos, a provider of network anti-virus solutions, and CipherTrust (later acquired by McAfee), a provider of email and internet security products.

Mr. Ranere frequently lends his time and legal advice to local community organizations, including TiE Boston, a nonprofit association dedicated to fostering entrepreneurship, and More Than Words, a nonprofit social enterprise empowering high-risk young adults to take charge of their lives.

Mr. Ranere's recent representative transactions include:

  • Amphenol – US$400 million acquisition of SSI Controls Technologies 
  • Charles River Systems – US$2.6 billion sale to State Street Corporation
  • CloudHealth – Sale to VMware, Inc. (terms undisclosed)
  • Kiniksa Pharmaceuticals – US$150 million IPO
  • Actifio – US$100 million debt and equity financing led by Crestline Investors
  • Rapid Micro Biosystems – US$60 million equity financing led by Bain Capital Life Sciences
  • Veracode – US$614 million sale to CA Technologies    
  • The Echo Nest – Sale to Spotify (terms undisclosed)

Other notable clients and transactions include:

  • Care.com – IPO and numerous acquisitions
  • Zipcar – IPO and sale to Avis Budget Group
  • Equity financings and other transactions for company clients Alignable, Catalant Technologies, CounterTack, Humanyze, Klaviyo, Vestmark, and many others
  • Equity investments in emerging technology companies for investor clients 3L Capital, General Catalyst Partners, and Burda Principal Investments
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.